重组人血小板生成素与白介素-11治疗白血病化疗后血小板减少症临床疗效

目的 以重组白介素-11为对照,探讨重组入血小板生成素治疗白血病化疗后血小板减少的临床疗效及安全性.方法 选择2012年8月至2014年10月在本院接受白血病化疗的60例患者作为研究对象,随机分为研究组(重组人血小板生成素)和对照组(重组白介素-11),观察外周血小板动态变化.结果 两组化疗4d时对比差异无统计学意义(P＞0.05);化疗12 d时研究组显著高于对照组(P＜0.05);至化疗24 d时两组比较差异无统计学意义(P＞0.05).研究组PLT＜30×109/L持续时间、恢复至75×109./L或125×109/L时间均短于对照组(P＜0.05).结论 相比白介素-11,化疗后辅助重组人血小板生成素治疗更利于减少血小板下降幅度及持续时间,且副作用小,安全有效,值得临床推广应用.

Recombinant human thrombopoietin versus interleukin-11 in treatment of chemotherapy-induced thrombocytopenia in patients with leukemia

Objective To explore the clinical curative effect and safety of recombinant human thrombopoietin versus recombinant interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia in patients with leukemia.Methods 60 patients with leukemia treated with chemotherapy at our hospital from August,2010 to August,2014 were selected as study objects and were randomly divided into a study group,treated with recombinant human thrombopoietin,and a control group,treated with recombinant interleukin-11.The dynamic change of peripheral platelet count was observed.Results There was no statistical difference (P＞0.05) between these two groups 4 days after chemotherapy;the peripheral platelet count of the study group was significantly higher than that of the control group 12 days after chemotherapy (P＜0.05);and there was no statistical difference (P＞0.05)between these two groups 24 days after chemotherapy.The time of platelet count less than PLT ＜30× 109/L and the times for platelet count recovering to 75× 109/L or 125× 109/L were all shorter in the study group than in the control group (P ＜ 0.05).Conclusions In comparison with intedeukin 11,adjuvant therapy after chemotherapy in the treatment of thrombocytopenia is even more helpful to control the decrease of platelet and minimize the duration of the decrease of platelet,and it is safe and effective with minor side effect,and it is worth being clinically generalized.